Whitehawk Therapeutics (WHWK) CFO Giacobello received 118,476 Stock Option (right to buy)
Insider transactions reported
Scott M. Giacobello (Chief Financial Officer at Whitehawk Therapeutics Inc., WHWK) reported that they received 118,476 Stock Option (right to buy) on Sep 15, 2026.
- Reporting person
- Giacobello Scott M.
- Role
- CHIEF FINANCIAL OFFICER
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Grant or award (A) | Stock Option (right to buy)On 118,476 Common Stock1 | +118,476 | - | - | 118,476 direct |
| Sep 15, 2026 | Grant or award (A) | Restricted Stock UnitsOn 118,476 Common Stock2, 3 | +118,476 | - | - | 118,476 direct |
Holdings before and after
- Stock Option (right to buy): 0 to 118,476 direct
- Restricted Stock Units: 0 to 118,476 direct
Footnotes from the filing
- 1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
- 2. Each restricted stock unit ( RSU ) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
- 3. The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Giacobello report in this WHWK Form 4?
Scott M. Giacobello (Chief Financial Officer at Whitehawk Therapeutics Inc., WHWK) reported that they received 118,476 Stock Option (right to buy) on Sep 15, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for WHWK
Across the 28 sessions after earlier WHWK headlines, the stock closed higher 12 times and lower 16 times, with a median move of 3.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | WHWK | SPY |
|---|---|---|---|
| Sep 14, 2026 | Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 | -1.0% | -0.4% |
| Sep 11, 2026 | Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors | +1.0% | +0.9% |
| Sep 2, 2026 | Whitehawk Therapeutics to Participate in Upcoming Investor Conferences | +1.7% | +0.4% |
| Aug 6, 2026 | Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | +15.5% | -0.2% |
| Jul 13, 2026 | Leerink Partners initiated coverage on Whitehawk Therapeutics with a new price target | -3.3% | -0.8% |
| Jul 7, 2026 | Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development | +3.2% | -0.5% |
Earlier insider filings at WHWK
- Sep 18, 2026Amendment: SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James
- Sep 18, 2026Amendment: SEC Form 4 filed by Officer Ball Bryan
- Sep 18, 2026Amendment: SEC Form 4 filed by Chief Scientific Officer Dornan David
- Sep 18, 2026Amendment: SEC Form 4 filed by Chief Medical Officer Dugan Margaret
- Sep 15, 2026SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Lennon David James
Keep researching WHWK
- WHWK insider tradesEvery buy and sale reported by Whitehawk Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- WHWK financial statementsRevenue, profit, cash flow and balance sheet from Whitehawk Therapeutics Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow WHWK and get a push notification the moment its next story breaks.